Undervalued Drug Manufacturer Stocks on NAS September 2023

September 23, 2023

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
VTRS Viatris 9.69 12.00 23.84 8655389 11662 4.95 6.3
EVO Evotec 10.21 12.20 19.51 46796 3613 0.00 0.0
LNTH Lantheus Holdings 60.27 67.73 12.38 889983 4280 0.00 123.0
DVAX Dynavax Technologies 13.73 14.78 7.64 1465382 2089 0.00 18.8
BIIB Biogen 258.93 273.58 5.66 748998 37674 0.00 14.1
INDV Indivior 22.01 22.96 4.31 9742 3141 0.00 0.0
GILD Gilead Sciences 75.27 77.89 3.48 5358040 94690 3.96 17.3
SNY Sanofi 54.28 54.99 1.32 1126572 135765 3.50 14.8
AZN AstraZeneca 67.02 67.41 0.58 4014964 209102 2.16 33.9
All data provided as at market close September 20, 2023.

Company Details

Viatris

VTRS:NAS

Close Price

9.69

Our Valuation

12.00

% Difference

23.84

Market Cap ($M)

11662

P/E Ratio

6.3

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales.

Access the stockcalc valuation


Evotec

EVO:NAS

Close Price

10.21

Our Valuation

12.20

% Difference

19.51

Market Cap ($M)

3613

P/E Ratio

0.0

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate.

Access the stockcalc valuation


Lantheus Holdings

LNTH:NAS

Close Price

60.27

Our Valuation

67.73

% Difference

12.38

Market Cap ($M)

4280

P/E Ratio

123.0

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer.

Access the stockcalc valuation


Dynavax Technologies

DVAX:NAS

Close Price

13.73

Our Valuation

14.78

% Difference

7.64

Market Cap ($M)

2089

P/E Ratio

18.8

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Biogen

BIIB:NAS

Close Price

258.93

Our Valuation

273.58

% Difference

5.66

Market Cap ($M)

37674

P/E Ratio

14.1

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017.

Access the stockcalc valuation


Indivior

INDV:NAS

Close Price

22.01

Our Valuation

22.96

% Difference

4.31

Market Cap ($M)

3141

P/E Ratio

0.0

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world.

Access the stockcalc valuation


Gilead Sciences

GILD:NAS

Close Price

75.27

Our Valuation

77.89

% Difference

3.48

Market Cap ($M)

94690

P/E Ratio

17.3

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.

Access the stockcalc valuation


Sanofi

SNY:NAS

Close Price

54.28

Our Valuation

54.99

% Difference

1.32

Market Cap ($M)

135765

P/E Ratio

14.8

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron.

Access the stockcalc valuation


AstraZeneca

AZN:NAS

Close Price

67.02

Our Valuation

67.41

% Difference

0.58

Market Cap ($M)

209102

P/E Ratio

33.9

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Viatris and Evotec are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-september-2023
Viatris $VTRS and Evotec $EVO are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-september-2023
Viatris and Evotec are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-september-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.